Related Experiment Videos
Cost-effectiveness issues in hypertension control
1Marion Merrell Dow Canada, Inc., Laval, Quebec.
Insights
Treating hypertension is cost-effective, with medication costs offset by reduced stroke expenses. Improving patient identification and compliance, especially with once-daily medications, lowers overall healthcare costs.
Area of Science:
- Health economics
- Cardiovascular disease management
Background:
- Healthcare systems face increasing pressure to assess the cost-effectiveness of treatments.
- Hypertension treatment is recognized as highly cost-effective, with significant savings potential.
Purpose of the Study:
- To evaluate the economic impact of hypertension treatment and management strategies.
- To highlight the cost-effectiveness of improving patient identification and medication compliance.
Main Methods:
- Analysis of cost-effectiveness in hypertension treatment.
- Comparison of medication costs versus healthcare savings (e.g., stroke reduction).
- Evaluation of compliance strategies and their economic implications.
Main Results:
- The cost of hypertension medication is outweighed by savings from stroke prevention alone.
- Underidentification of hypertensive patients leads to underprescribing and increased long-term costs.
- Regimens promoting patient compliance, such as once-daily formulations, reduce overall treatment expenses.
Conclusions:
- Optimizing hypertension management through better identification and compliance is economically beneficial.
- Prioritizing patient compliance with antihypertensive medications leads to improved health outcomes and reduced healthcare utilization.
- Investing in cost-effective hypertension treatment strategies improves quality of life and reduces societal costs.
Abstract:
In recent years, significant attention has been directed to the economics of health care. Pressures continue to mount to evaluate the cost-effectiveness of treating specific conditions and of utilizing specific treatment regimens. It has been demonstrated that the treatment of hypertension is very cost-effective. In fact, the total cost of hypertensive medication is more than offset by the savings from stroke alone. There is significant underidentification of hypertensive patients and therefore underprescribing of antihypertensive medications. Better identification would involve increased medication costs, but these should be more than offset by reduced hospital costs, improved productivity and enhanced quality of life. In selecting antihypertensive agents, particular attention should be given to the use of regimens that facilitate patient compliance. Once- or twice-a-day formulations, even when they are more expensive than formulations given three or four times daily, can result in lower overall treatment costs due to greater rates of compliance, better hypertension control and less use of physician, hospital and laboratory services.